Patient
|
Age (Sex)
|
Tumor size (cm)
|
TNM stage
|
Tumor histology
|
ARMS-PCR
|
Tumor puritya
|
Treatment
|
Disease outcomec (months)
|
---|
1°
|
2°
|
1°
|
2°
|
1°
|
2°
|
1°
|
2°
|
1°
|
2°
|
---|
P1
|
50 (F)
|
1.8 × 2.0
|
1.6 × 1.7
|
cT3N2M1b IVa
|
AD
|
MAD
|
E19 del
|
NT
|
55%
|
51%
|
Gefitinib + RT
|
Progressive (8)
|
Progressive (8)
|
P2
|
70 (M)
|
2.3 × 1.7
|
3.3 × 2.5
|
cT4N0M1b IVa
|
AD
|
MAD
|
E19 del
|
NT
|
31%
|
20%
|
Gefitinib + RT
|
Stable (18)
|
Stable (18)
|
P3
|
54 (M)
|
2.3 × 1.7
|
3.0 × 2.0
|
cT1N2M1b IVa
|
AD
|
MAD
|
E19 del
|
NT
|
50%
|
45%
|
Gefitinib + RT
|
Stable (10)
|
Progressive (10)
|
P4
|
54 (F)
|
3.4 × 3.0
|
5.3 × 3.1
|
cT2N3M1b IVb
|
AD
|
MAD
|
E19 del
|
NT
|
37%
|
35%
|
Gefitinib + RT
|
Progressive (14)
|
Progressive (14)
|
P5
|
73 (F)
|
2.6 × 1.7
|
4.3 × 2.8
|
cT2N0M1c IVb
|
AD
|
MAD
|
E19 del
|
NT
|
52%
|
52%
|
Gefitinib + RT
|
Progressive (18)
|
Stable (18)
|
P6
|
67 (M)
|
4.4 × 2.8
|
2.5 × 1.8
|
cT2N2M1b IVa
|
AD
|
MAD
|
E19 del
|
NT
|
26%
|
32%
|
Gefitinib + RT
|
Stable (5)
|
Stable (5)
|
P7
|
64 (F)
|
2.7 × 2.1
|
2.1 × 1.8
|
cT2N2M1b IVa
|
P-NSCC
|
MAD
|
L858R
|
NT
|
24%
|
37%
|
Gefitinib
|
Deceased (7)
|
Deceased (7)
|
P8
|
54 (F)
|
2.8 × 2.4
|
1.5 × 0.9
|
cT1N1M1b IVa
|
AD
|
MAD
|
L858R
|
NT
|
31%
|
34%
|
Gefitinib + CT + RT
|
Progressive (3)
|
Stable (3)
|
P9
|
61 (F)
|
3.2 × 2.8
|
2.5 × 2.4
|
cT2N3M1c IVb
|
AD
|
MAD
|
L858R
|
NT
|
60%
|
57%
|
Erlotinib + CT
|
Progressive (7)
|
Stable (7)
|
P10
|
50 (M)
|
1.7 × 0.6
|
1.9 × 1.7
|
cT1bN0M1c IVb
|
AD
|
MAD
|
–
|
L858R
|
24%
|
25%
|
Osimertinib
|
Stable (4)
|
Stable (4)
|
P11
|
66 (M)
|
1.5 × 1.3
|
2.6 × 1.3
|
cT1bN2M1c IVb
|
AD
|
MAD
|
–
|
L858R
|
94%
|
30%
|
Gefitinib
|
Progressive (17)
|
Stable (17)
|
P12
|
49 (M)
|
2.6 × 1.5
|
3.6 × 1.1
|
cT3N0M1c IVb
|
AD
|
MAD
|
G719Xb
|
NT
|
47%
|
51%
|
Osimertinib + RT
|
Progressive (12)
|
Stable (12))
|
P13
|
59 (M)
|
5.6 × 6.3
|
1.2 × 1.4
|
cT3N0M1c IVb
|
AD
|
MAD
|
L861Q
|
NT
|
67%
|
79%
|
Gefitinib
|
Deceased (14)
|
Deceased (14)
|
P14
|
52 (M)
|
2.0 × 1.7
|
2.5 × 2.7
|
cT1N2M1b IVa
|
AD
|
MAD
|
EML4-ALK
|
NT
|
70%
|
33%
|
Crizotinib + RT
|
Stable (13)
|
Stable (13)
|
P15
|
63 (M)
|
3.4 × 3.7
|
7.4 × 7.9
|
cT2N2M1c IVb
|
AD
|
MAD
|
–
|
NT
|
47%
|
49%
|
CT
|
Progressive (5)
|
Progressive (5)
|
P16
|
53 (F)
|
4.2 × 7.4
|
2.1 × 2.3
|
cT4N0M1a IVb
|
AD
|
MAD
|
–
|
NT
|
35%
|
35%
|
CT + RT
|
Stable (3)
|
Stable (3)
|
P17
|
53 (M)
|
3.2 × 1.9
|
4.4 × 1.8
|
cT2N2M1b IVa
|
AD
|
MAD
|
–
|
NT
|
33%
|
74%
|
CT + RT
|
Deceased (2)
|
Deceased (2)
|
- aTumor purity was defined as the ratio of tumor to normal cells. bARMS-PCR cannot determine the precise amino acid change (X). AD Adenocarcinoma, P-NSCC Poorly differentiated non-small cell carcinoma, MAD Metastatic adenocarcinoma, NT Not tested, CT Chemotherapy, RT Radiotherapy cProgressive disease, defined as > 20% increase in tumor size. Stable disease, defined as either no change or < 20% change in tumor size